Angeles Health provides Stem Cell Treatment for Stroke Patients. Stroke is the USA’s third leading cause of death, behind only heart disease and cancer. Stroke data indicates incidences may be increasing. Recent data compiled by the American Heart Association (AHA) for 2008 shows that the annual incidence of new or recurrent stroke in the United States is about 780,000, with approximately 600,000 of these strokes being first attacks. Here is the inclusion and exclusion criteria for stem cell application for stroke.
• Males and Females between Age 18 and 80 years.
• Symptoms and signs of clinically definite ischemic stroke or hemorrhagic stroke
• DWI-MRI has reliably shown relevant ischemic lesions
• Extracranial duplex/transcranial Doppler must confirm intra/extracranial arteries permeability
• The stroke is severe (NIH Stroke Scale >= 8 before procedure)
At the time of the screening/enrollment visit #1, patients meeting ANY ONE of the following criteria will be excluded from the study.
• Females who are pregnant or nursing or females of childbearing potential who are unwilling to maintain contraceptive therapy for the duration of the study
• Inability to undergo fat transfer procedure or have any medical problems that contraindicate the procedure.
• Life expectancy < 6 months due to concomitant illnesses. • Exposure to any investigational drug or procedure within 1 month prior to study entry or enrolled in a concurrent study that may confound results of this study. • Active infectious disease and/or known to have tested positive for HIV, HTLV, HBV, HCV, CMV (IgM > IgG) and/or syphilis. If the panel includes antibodies to the HBV-cAg and HBV-sAg, then an expert will be consulted as to patient eligibility based on the patient’s infectious status
• Any illness which might affect a patient’s survival over the follow-up period
• Any illness which, in the Investigator’s judgement, will interfere with the patient’s ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of the study results
• Patients on chronic immunosuppressive transplant therapy
• Patients with severe coagulation disorders
• Systolic blood pressure (supine) ≤90 mmHg;
• Resting heart rate > 100 bpm;
• Medical risk that precludes anesthesia (conscious sedation), or ASA Class 5.
• Active clinical infection being treated by antibiotics within one week of enrollment.
• Known drug or alcohol dependence or any other factors which will interfere with the study conduct or interpretation of the results or who in the opinion of the investigator are not suitable to participate.
• COPD or severe asthma that would contraindicate surgery
• History of cancer (other than non-melanoma skin cancer or in-situ cervical cancer) in the last two years.
• Unwilling and/or not able to give written informed consent.